Lung transplant recipients (LuTxR) are at greater risk of COVID-19 and have attenuated response to vaccinations. In Italy, immu- nocompromised patients received the indication to be administered mRNA vaccines only. We aimed to evaluate the safety and immunogenicity of these vaccines in our cohort of LuTxR; we are now presenting the prelimi- nary data of their serologic responses
Safety and Immunogenicity of the AntiCOVID19 Vaccines in a Cohort of Lung Transplant Recipients / L. Morlacchi, V. Rossetti, S.U. Renteria, I. Righi, F. Ceriotti, L. Rosso, F. Blasi. - In: THE JOURNAL OF HEART AND LUNG TRANSPLANTATION. - ISSN 1053-2498. - 42:4 Supplement(2023 Apr), pp. 692.S306-692.S307. (Intervento presentato al 42. convegno ISHLT Annual Meeting and Scientific Sessions : April, 19 - 22 tenutosi a Denver (CO USA) nel 2023) [10.1016/j.healun.2023.02.706].
Safety and Immunogenicity of the AntiCOVID19 Vaccines in a Cohort of Lung Transplant Recipients
L. RossoPenultimo
;F. BlasiUltimo
2023
Abstract
Lung transplant recipients (LuTxR) are at greater risk of COVID-19 and have attenuated response to vaccinations. In Italy, immu- nocompromised patients received the indication to be administered mRNA vaccines only. We aimed to evaluate the safety and immunogenicity of these vaccines in our cohort of LuTxR; we are now presenting the prelimi- nary data of their serologic responses
| File | Dimensione | Formato | |
|---|---|---|---|
|
ISHLT 2023 (Safety and Immunogenicity....).pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.07 MB
Formato
Adobe PDF
|
1.07 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
